Results from a phase III clinical trial have revealed two years of treatment with oral Gilenya (fingolimod) significantly reduced the rate of relapses when compared to Avonex (interferon beta-1a)...
If a person with multiple sclerosis (MS) experiences fatigue they often make several behavioural changes, such as resting and limiting activity. This can result in an unevenly spread activity pattern...
A phase III study of statins for secondary progressive multiple sclerosis (SPMS) has begun.
Headed up by University College London Hospital Consultant Neurologist Jeremy Chataway, the trial will...
The prevalence and definition of benign multiple sclerosis (BMS) remain controversial. Most definitions are based on the Expanded Disability Status Scale (EDSS), not encompassing the wider impact of...
Exercise has been shown to benefit people living with multiple sclerosis (MS), but for those with severe mobility impairment more specialised adapted exercise equipment, such as functional electrical...
The National Institute for Health and Care Excellence (NICE) has revealed it will not recommend ocrelizumab for the treatment of primary progressive multiple sclerosis (PPMS).
There are currently no...
Active Biotech has regained the global development and commercialisation rights to laquinimod from Teva Pharmaceutical Industries. Teva's decision to return the rights is based on the fact that Teva...
Sexual dysfunction is a common symptom of multiple sclerosis (MS) that often goes unreported by both the patient and the clinician. Sexual dysfunction can affect a person's mood, relationships, daily...
A team led by neurologist Roland Martin and immunologist Mireia Sospedra at the University of Zurich (UZH), the University Hospital Zurich (USZ) and researchers at the Karolinska Institute in Sweden...
Results from a clinical trial of more than 250 people with progressive multiple sclerosis (MS) have revealed an existing asthma drug called ibudilast was better than a placebo or dummy drug in...
